AbstractHIVViral Hepatitis and Liver DiseaseAcceptability and concerns over the use of PrEP in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-USView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseClinical case presentation: A preliminary profile of common co-morbidities and risk practices in a sample of HIV/HCV co-infected patients in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHurricane Maria’s viral impact: HIV care outcomes among substance users in Puerto Rico following hurricane MariaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseProvider-Initiated HIV testing predictors among heterosexuals at increased risk of HIV in Puerto Rico: Data from NHBS – HET cycle, 2016View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSociodemographic, health-related factors and behavioral practices among people who inject drugs: Data from the PR NHBS-PWID 3 (2012) and NHBS-PWID 4 (2015)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAssociations between hepatitis C and social determinants of health in a sample of injecting drug users living with HIV in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTenofovir alafenamide vs tenofovir DF in women: Pooled analysis of 7 clinical trialsView Abstract
AbstractHIVViral Hepatitis and Liver Disease96 Week efficacy and safety of B/F/TAF in treatment-naïve adults and adults ≥ 50 yearsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAutomated electrochemiluminescence assay could be used for screening hepatitis B and C markers in dried blood spot samples?View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHeterogeneity in priorities for continuing education training among clinicians providing (or not!) HIV and HCV clinical servicesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEfficacy and safety of sofosbuvir/velpatasvir for the treatment of patients with chronic hepatitis C genotype 1-6 infection: Integrated analysis of eight Phase 3 clinical trialsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePrevalence of alcohol and substance use in a sample of patients living with HIV/HCV co-infection who are in routine clinical care receiving antiretroviral therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTime to treatment disfavors patients living with HIV/HCV co-infectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHigh prevalence of hepatitis B virus infection among chronic kidney disease patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImplementation science for HIV prevention using an eHealth program for Spanish-speaking sexual minorities groups in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-USView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseClinical case presentation: A preliminary profile of common co-morbidities and risk practices in a sample of HIV/HCV co-infected patients in Puerto RicoView Abstract
